ArticleIJU case reports2026
Long-Term Response to Avelumab Maintenance Therapy and Durable Remission After Cessation in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metastatic urothelial carcinoma (UC) of the renal pelvis is an aggressive malignancy with a poor prognosis. Although avelumab maintenance therapy is a standard of care for advanced UC, long-term durable remission after treatment cessation is rare. Case Presentation: We report the case of a 71-year-old female with metastatic UC of the renal pelvis who achieved a partial response to gemcitabine and cisplatin chemotherapy. She subsequently underwent 40 courses of avelumab maintenance therapy, which she later chose to discontinue. The partial response initially achieved with gemcitabine and cisplatin chemotherapy has been maintained for over 2 years without further intervention following the cessation of avelumab maintenance therapy. Conclusion: This case highlights avelumab's potential to induce a profound and durable antitumor immune response, suggesting the possibility of a "functional cure" in a subset of patients. This provides valuable data for guiding clinical decisions on the optimal duration of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.